CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Highlights Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 12/06/2025 BST			5-day change	1st Jan Change
151.89 ^USD	+0.52%		+7.57%	-17.72%

06-09	Charles River Laboratories International, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10:00 AM
06-04	Charles River Laboratories International, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 10:30 AM

Highlights

Charles River Laboratories International to Seek Strategic M&A	06-03	CI
London Calling: Markets Jump	05-08
Top Midday Gainers	05-07	MT
Charles River raises 2025 profit forecast, reaches deal with activist investor	05-07	RE
Charles River Laboratories International, Inc. Announces Board Changes	05-07	CI
Charles River Laboratories International, Inc. Revises Earnings Guidance for Year 2025	05-07	CI
Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on August 7, 2024.	05-07	CI
Charles River Laboratories Q1 Non-GAAP Earnings Rise, Revenue Falls	05-07	MT
Charles River to add new directors, review business in agreement with Elliott	05-07	RE
Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 29, 2025	05-07	CI
Earnings Flash (CRL) Charles River Laboratories International Posts Q1 Revenue $984.2M, vs. FactSet Est of $941.9M	05-07	MT
Earnings Flash (CRL) Charles River Laboratories International Reports Q1 Adjusted EPS $2.34, vs. FactSet Est of $2.07	05-07	MT
Charles River Laboratories International, Inc. Announces Inaugural Advanced Therapy Incubator Program Cohort	04-29	CI
Charles River Laboratories International, Inc. Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development	04-22	CI
Flagship Pioneering, Pfizer, Charles River and Valo Health Collaborate to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease	04-01	CI
Charles River and Valo Health Identify A Potential Therapeutic for Lupus Using Logica	03-25	CI
Tariff Tantrums Tumble Stocks	03-04
FairJourney Biologics, S.A. acquired South San Francisco Assets of Charles River Laboratories International, Inc..	03-03	CI
Charles River Laboratories International, Inc. Announces Agreement with Singapore General Hospital	02-25	CI
Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on August 7, 2024.	02-19	CI
Charles River beats quarterly estimates on stable demand for drug development services	02-19	RE
Charles River Laboratories Q4 Higher Earnings Higher, Revenue Lower; 2025 Guidance Issued	02-19	MT
Earnings Flash (CRL) Charles River Laboratories International Reports Q4 Revenue $1B, vs. FactSet Est of $983.6M	02-19	MT
Earnings Flash (CRL) Charles River Laboratories International Reports Q4 Adjusted EPS $2.66, vs. FactSet Est of $2.53	02-19	MT
Charles River Laboratories International, Inc. Provides Earnings Guidance for the Year 2025	02-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Highlights

Filters